Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Zheng, Guoping ^a   Huang, Lanfang ^a   Tong, Haijiang ^a   Shu, Qiang ^b   Hu, Yaoqin ^b   Ge, Menghua ^a   Deng, Keqin ^a   Zhang, Liuya ^a   Zou, Bin ^a   Cheng, Baoli ^c   Xu, Jianguo ^a,c  

^a Shaoxing Second Hospital   (China)

^b CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute respiratory distress syndrome; Adipose derived; Biomarkers; Mesenchymal stem cells

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; SURFACTANT PROTEIN D;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC ADIPOSE DERIVED MESENCHYMAL STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL TISSUE; APACHE; ARTERIAL OXYGEN TENSION; ARTICLE; ASPIRATION PNEUMONIA; BREATHING RATE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MESENCHYMAL STEM CELL; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; UREA NITROGEN BLOOD LEVEL; ADIPOSE TISSUE; AGED; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CONTROLLED CLINICAL TRIAL; CYTOLOGY; FOLLOW UP; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; TRANSPLANTATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MIDDLE AGED; PILOT PROJECTS; RESPIRATORY DISTRESS SYNDROME, ADULT; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899483580     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-39     Document Type: Article

References (44)

1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012, 122:2731-2740. 10.1172/JCI60331, 3408735, 22850883.
2. Walkey AJ, Summer R, Ho V, Alkana P. Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol 2012, 4:159-169. 3410685, 22866017.
3. Cardenes N, Caceres E, Romagnoli M, Rojas M. Mesenchymal stem cells: a promising therapy for the acute respiratory distress syndrome. Respiration 2013, 85:267-278. 10.1159/000347072, 23428562.
4. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler RM, Fibbe WE, Locatelli F. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011, 46:200-207. 10.1038/bmt.2010.87, 20400983.
5. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286. 10.1016/j.jacc.2009.06.055, 3580848, 19958962.
6. Wang D, Akiyama K, Zhang H, Yamaza T, Li X, Feng X, Wang H, Hua B, Liu B, Xu H, Chen W, Shi S, Sun L. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:273291. 3399403, 22829849.
7. de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013, 28:313-323. 10.1007/s00384-012-1581-9, 23053677.
8. Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001, 82:583-590. 10.1002/jcb.1174, 11500936.
9. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003, 33:919-926. 10.1016/j.bone.2003.07.005, 14678851.
10. Mosna F, Sensebe L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev 2010, 19:1449-1470. 10.1089/scd.2010.0140, 20486777.
11. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005, 33:145-152. 10.1165/rcmb.2004-0330OC, 2715309, 15891110.
12. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, Rojas M. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007, 293:L131-L141. 10.1152/ajplung.00431.2006, 17416739.
13. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003, 100:8407-8411. 10.1073/pnas.1432929100, 166242, 12815096.
14. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179:1855-1863.
15. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007, 4:e269. 10.1371/journal.pmed.0040269, 1961632, 17803352.
16. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S, Yip HK. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med 2011, 9:118. 10.1186/1479-5876-9-118, 3155151, 21781312.
17. Martinez-Gonzalez I, Roca O, Masclans JR, Moreno R, Salcedo MT, Baekelandt V, Cruz MJ, Rello J, Aran JM. Human mesenchymal stem cells overexpressing the IL-33 antagonist sST2 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 2013, 49:552-562. 10.1165/rcmb.2012-0406OC, 23656573.
18. Chien MH, Bien MY, Ku CC, Chang YC, Pao HY, Yang YL, Hsiao M, Chen CL, Ho JH. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit Care Med 2012, 40:1245-1253. 10.1097/CCM.0b013e31823bc89a, 22202710.
19. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:2526-2533.
20. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome The acute respiratory distress syndrome network. N Engl J Med 2000, 342:1301-1308. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.
21. Hodgson CL, Tuxen DV, Davies AR, Bailey MJ, Higgins AM, Holland AE, Keating JL, Pilcher DV, Westbrook AJ, Cooper DJ, Nichol AD. A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. Crit Care 2011, 15:R133. 10.1186/cc10249, 3219001, 21635753.
22. Schutte H, Lohmeyer J, Rosseau S, Ziegler S, Siebert C, Kielisch H, Pralle H, Grimminger F, Morr H, Seeger W. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J 1996, 9:1858-1867. 10.1183/09031936.96.09091858, 8880103.
23. Agrawal A, Zhuo H, Brady S, Levitt J, Steingrub J, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Matthay MA, Liu KD. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol 2012, 303:L634-L639. 10.1152/ajplung.00195.2012, 3469636, 22865551.
24. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP. Network NARDSCT: lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005, 33:1-6. discussion 230-232.
25. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. National heart L, blood institute acute respiratory distress syndrome clinical trials N: pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007, 35:1821-1828. 10.1097/01.CCM.0000221922.08878.49, 2764536, 17667242.
26. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004, 170:766-772. 10.1164/rccm.200310-1434OC, 15201135.
27. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Acute respiratory distress syndrome N: plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003, 58:983-988. 10.1136/thorax.58.11.983, 1746524, 14586055.
28. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009, 18:683-692. 10.1089/scd.2008.0253, 3190292, 19099374.
29. Weiss DJ, Casaburi R, Flannery R, Leroux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013, 143:1590-1598. 10.1378/chest.12-2094, 23172272.
30. Van RL, Bayliss CE, Roncari DA. Cytological and enzymological characterization of adult human adipocyte precursors in culture. J Clin Invest 1976, 58:699-704. 10.1172/JCI108516, 333228, 956396.
31. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228. 10.1089/107632701300062859, 11304456.
32. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci 2009, 1176:101-117. 10.1111/j.1749-6632.2009.04607.x, 19796238.
33. Qayyum AA, Haack-Sorensen M, Mathiasen AB, Jorgensen E, Ekblond A, Kastrup J. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen Med 2012, 7:421-428. 10.2217/rme.12.17, 22594332.
34. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591. 10.1634/stemcells.2006-0228, 16873762.
35. Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, Tivchev P, Altunkova I, Kyurkchiev DS. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009, 126:37-42. 10.1016/j.imlet.2009.07.010, 19647021.
36. Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2007, 20:867-876. 10.1159/000110447, 17982269.
37. Vanikar AV, Dave SD, Thakkar UG, Trivedi HL. Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int 2010, 2010:582382. 3010655, 21197448.
38. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39:3358-3362. 10.1016/j.transproceed.2007.08.103, 18089385.
39. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, Miller-Podraza H, Blomqvist M, Olonen A, Salo H, Lehenkari P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007, 25:197-202. 10.1634/stemcells.2006-0444, 17008421.
40. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007, 92:1208-1215. 10.3324/haematol.11446, 17666368.
41. Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailander V, Lotfi R, Ignatius A, Sensebe L, Bourin P, Schrezenmeier H, Rojewski MT. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554. 10.3109/14653249.2012.655420, 3400099, 22296115.
42. Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander AR. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004, 32:1212-1225. 10.1016/j.exphem.2004.09.003, 15588946.
43. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005, 23:1357-1366. 10.1634/stemcells.2005-0094, 16081661.
44. Patrikoski M, Juntunen M, Boucher S, Campbell A, Vemuri MC, Mannerstrom B, Miettinen S. Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells. Stem Cell Res Ther 2013, 4:27. 10.1186/scrt175, 3707027, 23497764.